<DOC>
	<DOCNO>NCT02536976</DOCNO>
	<brief_summary>There high prevalence OAB symptom among patient Parkinson 's disease lack pharmacotherapies acceptable side effect profile . Specifically , available anticholinergic medication high risk cognitive side-effects , preclude use PD patient CI . PD also cause number non-motor symptom likely adversely affect currently available anticholinergic agent . Mirabegron first pharmacologic treatment may exacerbate CI , constipation , orthostatic hypotension ( OH ) , somnolence , dry mouth PD .</brief_summary>
	<brief_title>Mirabegron Parkinson Disease Impaired Cognition</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Aged 2580 screen . 2 . Ambulatory ( define able ambulate least 10 meter , without assistance ) . 3 . Clinical Diagnosis PD base United Kingdom Brain Bank diagnostic criterion PD . 4 . At baseline visit ( Visit 2 ) patient must : At least 8 micturition per 24 hour At least 3 urgency episode per 3day diary . 5 . A MoCA score 19 26 ( inclusive ) screening . 6 . Provide informed consent participate study understand may withdraw consent time without prejudice future medical care . 7 . Be cognitively capable , opinion investigator , understand provide inform consent . 8 . Be cognitively capable complete require questionnaire assessment , OR care partner willing capable assist completion task . 9 . Be stable regimen antiparkinson 's medication least 30 day prior screen , expect remain stable dose duration study . 10 . If take cognitive enhancer ( donepezil , rivastigmine , memantine , galantamine ) , must stable dose least 30 day prior screen , expect remain stable dose duration study . EXCLUSION CRITERIA : 1 . Known suspected alcohol substance abuse precede 12 month . 2 . Women pregnant breastfeeding . 3 . Women childbearing potential ( WOCP ) use least one method contraception . 4 . Patients severe renal impairment ( CLcr ≤ 29 mL/min , eGFR ≤ 29 mL/min/1.73 m2 ) , moderate severe hepatic impairment ( ChildPugh class B C ) . 5 . Patients bladder outlet obstruction ( BOO ) , opinion study urologist , would expose risk urinary retention treatment mirabegron . 6 . Patients treat drug metabolize CYP2D6 pathway . 7 . Patients supine systolic blood pressure ( SBP ) ≥ 180 mm Hg , diastolic blood pressure ( DBP ) ≥ 110 mm Hg . 8 . Clinically significant , uncontrolled cardiac arrhythmia , unstable angina , congestive heart failure ( NYHA Class 3 4 ) , history myocardial infarction precede 2 year . 9 . History cancer precede 2 year successfully treat , nonmetastatic , squamous cell basal cell carcinoma , cervical cancer situ . 10 . Any major urological procedure precede 90 day . 11 . Any major surgical procedure precede 30 day . 12 . Previously treat mirabegron within 60 day prior baseline visit ( Visit 2 ) , previously fail treatment mirabegron regardless duration timing treatment . 13 . Current previous , within 60 day precede baseline visit ( Visit 2 ) , treatment antimuscarinic agent OAB symptom ; , willingness use antimuscarinic agent duration study . 14 . Currently receive investigational drug receive investigational drug within 60 day precede baseline visit ( Visit 2 ) . 15 . Any condition laboratory test result , , opinion Investigator Study Urologist , might result increase risk patient , would affect participation study . 16 . Any patient , opinion Investigator , good candidate study able follow study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>mirabegron</keyword>
</DOC>